

Kwangsik Nho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6044048/publications.pdf>

Version: 2024-02-01

232
papers

9,851
citations

61984

43
h-index

43889

91
g-index

279
all docs

279
docs citations

279
times ranked

13812
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Co-methylation Network Analysis Identifies Novel DNA Methylation Signatures and Their Target Genes in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2023, 93, 842-851.	1.3	2
2	Integrative metabolomics and genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1260-1278.	0.8	57
3	Human microRNA (miR-20b-5p) modulates Alzheimer's disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer's biomarkers. <i>Molecular Psychiatry</i> , 2022, 27, 1256-1273.	7.9	26
4	APOE ϵ 2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. <i>Alzheimer's and Dementia</i> , 2022, 18, 2151-2166.	0.8	16
5	Associations between Cortical Thickness and Metamemory in Alzheimer's Disease. <i>Brain Imaging and Behavior</i> , 2022, , 1.	2.1	2
6	Deep learning-based identification of genetic variants: application to Alzheimer's disease classification. <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.5	26
7	Genome-wide association study of brain arteriolosclerosis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1437-1450.	4.3	2
8	PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer's disease. <i>Genome Medicine</i> , 2022, 14, 17.	8.2	34
9	Integrative analysis of eQTL and GWAS summary statistics reveals transcriptomic alteration in Alzheimer brains. <i>BMC Medical Genomics</i> , 2022, 15, 93.	1.5	2
10	Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease. <i>Brain</i> , 2022, 145, 2541-2554.	7.6	26
11	Implications of Liver Enzymes in the Pathogenesis of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1371-1376.	2.6	7
12	MicroRNA-298 reduces levels of human amyloid- β precursor protein (APP), β -site APP-converting enzyme 1 (BACE1) and specific tau protein moieties. <i>Molecular Psychiatry</i> , 2021, 26, 5636-5657.	7.9	61
13	Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. <i>Molecular Psychiatry</i> , 2021, 26, 309-321.	7.9	47
14	OUP accepted manuscript. <i>Brain</i> , 2021, , .	7.6	7
15	Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression. <i>Brain Communications</i> , 2021, 3, fcab139.	3.3	21
16	ADAS-viewer: web-based application for integrative analysis of multi-omics data in Alzheimer's disease. <i>Npj Systems Biology and Applications</i> , 2021, 7, 18.	3.0	5
17	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	9.0	146
18	Shared Genetic Background Between Cerebrospinal Fluid Biomarkers and Risk for Alzheimer's Disease: A Two-Sample Mendelian Randomization Study. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1197-1207.	2.6	3

#	ARTICLE	IF	CITATIONS
19	Importance of GWAS in finding un-targeted genetic association of sporadic Alzheimer's disease. <i>Molecular and Cellular Toxicology</i> , 2021, 17, 233.	1.7	6
20	Integrative-omics for discovery of network-level disease biomarkers: a case study in Alzheimer's disease. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	8
21	Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study. <i>PLoS Medicine</i> , 2021, 18, e1003615.	8.4	38
22	INPP5D expression is associated with risk for Alzheimer's disease and induced by plaque-associated microglia. <i>Neurobiology of Disease</i> , 2021, 153, 105303.	4.4	63
23	Genome-wide association study identifies susceptibility loci of brain atrophy to NFIA and ST18 in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 102, 200.e1-200.e11.	3.1	11
24	Rare CASP6N73T variant associated with hippocampal volume exhibits decreased proteolytic activity, synaptic transmission defect, and neurodegeneration. <i>Scientific Reports</i> , 2021, 11, 12695.	3.3	8
25	Predictability of polygenic risk score for progression to dementia and its interaction with APOE ϵ 4 in mild cognitive impairment. <i>Translational Neurodegeneration</i> , 2021, 10, 32.	8.0	11
26	Alternative Splicing Regulation of Low-Frequency Genetic Variants in Exon 2 of TREM2 in Alzheimer's Disease by Splicing-Based Aggregation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9865.	4.1	10
27	Tau Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. <i>Annals of Neurology</i> , 2021, 90, 751-762.	5.3	19
28	BMI1 is associated with CSF amyloid- β 2 and rates of cognitive decline in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 164.	6.2	5
29	Association of peripheral blood DNA methylation level with Alzheimer's disease progression. <i>Clinical Epigenetics</i> , 2021, 13, 191.	4.1	29
30	Dysregulated expression levels of APH1B in peripheral blood are associated with brain atrophy and amyloid- β 2 deposition in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 183.	6.2	13
31	A missense variant in SHARPIN mediates Alzheimer's disease-specific brain damages. <i>Translational Psychiatry</i> , 2021, 11, 590.	4.8	10
32	Biomarker-based polygenic risk scores for profiling genetic susceptibility in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
33	Integrative analysis of eQTL and GWAS summary statistics reveals novel genes related to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
34	Impact of <i>PLCG2</i> expression on Microglial Biology and Disease Pathogenesis in Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2021, 17, e058740.	0.8	2
35	Association of peripheral blood DNA methylation levels with Alzheimer's disease progression. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
36	Lipidomic signatures for APOE genotypes provides new insights about mechanisms of resilience in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
37	Predictability of polygenic risk score for progression to dementia and its interaction with <i>APOE</i> ϵ 4 in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
38	Transcriptomics, metabolomics, lipidomics, metabolic flux and mGWAS analyses of sphingolipid pathway highlights novel drugs for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
39	INPP5D as a potential therapeutic target against Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e053236.	0.8	1
40	Novel polygenic risk score approach with transcriptome-based weighting for genetic risk prediction of late-onset Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e053960.	0.8	0
41	PLCG2 expression is associated with plaque-associated microglia in Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e054755.	0.8	0
42	Sex differences in the genetic architecture underlying resilience in AD.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e055010.	0.8	0
43	Investigating the importance of acylcarnitines in Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e056647.	0.8	1
44	Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation. <i>Molecular Psychiatry</i> , 2020, 25, 1859-1875.	7.9	191
45	Dysregulated Fc gamma receptor-mediated phagocytosis pathway in Alzheimer's disease: network-based gene expression analysis. <i>Neurobiology of Aging</i> , 2020, 88, 24-32.	3.1	28
46	Association of blood-based transcriptional risk scores with biomarkers for Alzheimer disease. <i>Neurology: Genetics</i> , 2020, 6, e517.	1.9	13
47	Alternative Splicing Regulation of an Alzheimer's Risk Variant in <i>CLU</i> . <i>International Journal of Molecular Sciences</i> , 2020, 21, 7079.	4.1	10
48	Volumetric GWAS of medial temporal lobe structures identifies an <i>ERC1</i> locus using ADNI high-resolution T2-weighted MRI data. <i>Neurobiology of Aging</i> , 2020, 95, 81-93.	3.1	7
49	Identification of functionally connected multi-omic biomarkers for Alzheimer's disease using modularity-constrained Lasso. <i>PLoS ONE</i> , 2020, 15, e0234748.	2.5	6
50	Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer's Disease. <i>Cell Reports Medicine</i> , 2020, 1, 100138.	6.5	102
51	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 5698.	12.8	76
52	Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, 1213-1223.	0.8	23
53	Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau. <i>Alzheimer's and Dementia</i> , 2020, 16, 1234-1247.	0.8	15
54	Genetic variants and functional pathways associated with resilience to Alzheimer's disease. <i>Brain</i> , 2020, 143, 2561-2575.	7.6	93

#	ARTICLE	IF	CITATIONS
55	Whole exome sequencing analysis identifies genes and pathways in sporadic early-onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037899.	0.8	0
56	Deep learning detection of informative features in [18F] flortaucipir PET for Alzheimer's disease classification. <i>Alzheimer's and Dementia</i> , 2020, 16, e041126.	0.8	0
57	Identification of concordant plasma lipid signatures in Alzheimer's disease: Validation between two independent studies of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042275.	0.8	0
58	Genetic risk prediction of late-onset Alzheimer's disease based on tissue-specific transcriptomic analysis and polygenic risk scores. <i>Alzheimer's and Dementia</i> , 2020, 16, e045184.	0.8	1
59	A network-based, multi-omics atlas for target identification and prioritization in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045594.	0.8	0
60	Serum metabolome informs neuroimaging biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045596.	0.8	0
61	Genome-wide study of the human lipidome and links to Alzheimer's disease risk. <i>Alzheimer's and Dementia</i> , 2020, 16, e045600.	0.8	1
62	Integrative metabolomics-genomics approach reveals that pathways related to the metabolism of acylcarnitines and amines are new potential targets of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045610.	0.8	1
63	Transcriptomic profiles underlying functional brain networks at different stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046163.	0.8	2
64	Genome-wide analysis of longitudinal Alzheimer's disease biomarker endophenotypes. <i>Alzheimer's and Dementia</i> , 2020, 16, e046295.	0.8	0
65	Endophenotype driven polygenic risk scores for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046766.	0.8	0
66	Serum triglycerides in Alzheimer disease. <i>Neurology</i> , 2020, 94, e2088-e2098.	1.1	63
67	Identification of Novel Genes Associated with Cortical Thickness in Alzheimer's Disease: Systems Biology Approach to Neuroimaging Endophenotype. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 531-545.	2.6	10
68	Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease. <i>Clinical Epigenetics</i> , 2020, 12, 84.	4.1	57
69	β -amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline. <i>Communications Biology</i> , 2020, 3, 352.	4.4	63
70	Sex and APOE ϵ 4 genotype modify the Alzheimer's disease serum metabolome. <i>Nature Communications</i> , 2020, 11, 1148.	12.8	115
71	Systems modeling of white matter microstructural abnormalities in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2020, 26, 102203.	2.7	12
72	Differential co-expression analysis reveals early stage transcriptomic decoupling in Alzheimer's disease. <i>BMC Medical Genomics</i> , 2020, 13, 53.	1.5	4

#	ARTICLE	IF	CITATIONS
73	Deep learning detection of informative features in tau PET for Alzheimer's disease classification. BMC Bioinformatics, 2020, 21, 496.	2.6	37
74	Brain-wide structural connectivity alterations under the control of Alzheimer risk genes. International Journal of Computational Biology and Drug Design, 2020, 13, 58.	0.3	7
75	APOE Promoter Polymorphism-219T/G is an Effect Modifier of the Influence of APOE ϵ 4 on Alzheimer's Disease Risk in a Multiracial Sample. Journal of Clinical Medicine, 2019, 8, 1236.	2.4	40
76	MildInt: Deep Learning-Based Multimodal Longitudinal Data Integration Framework. Frontiers in Genetics, 2019, 10, 617.	2.3	35
77	Targeted genetic analysis of cerebral blood flow imaging phenotypes implicates the INPP5D gene. Neurobiology of Aging, 2019, 81, 213-221.	3.1	30
78	Telomere Shortening in the Alzheimer's Disease Neuroimaging Initiative Cohort. Journal of Alzheimer's Disease, 2019, 71, 33-43.	2.6	14
79	Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Network Open, 2019, 2, e197978.	5.9	142
80	Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways. Scientific Reports, 2019, 9, 14498.	3.3	22
81	Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNI2 cohorts. Scientific Data, 2019, 6, 212.	5.3	15
82	Deep Learning in Alzheimer's Disease: Diagnostic Classification and Prognostic Prediction Using Neuroimaging Data. Frontiers in Aging Neuroscience, 2019, 11, 220.	3.4	406
83	Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 619-627.	2.4	45
84	Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nature Communications, 2019, 10, 409.	12.8	121
85	Initiation of antidepressant medication and risk of incident stroke: using the Adult Changes in Thought cohort to address time-varying confounding. Annals of Epidemiology, 2019, 35, 42-47.e1.	1.9	8
86	Progress in Polygenic Composite Scores in Alzheimer's and Other Complex Diseases. Trends in Genetics, 2019, 35, 371-382.	6.7	52
87	Identification of exon skipping events associated with Alzheimer's disease in the human hippocampus. BMC Medical Genomics, 2019, 12, 13.	1.5	17
88	Predicting Alzheimer's disease progression using multi-modal deep learning approach. Scientific Reports, 2019, 9, 1952.	3.3	178
89	P4489: GENETIC ASSOCIATION OF IMMUNE-RELATED PROTEOMIC ANALYTES FROM PERIPHERAL BLOOD IN MCI AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1499.	0.8	0
90	ICP057: DYSREGULATED FC GAMMA R-MEDIATED PHAGOCYTOSIS PATHWAY IN ALZHEIMER'S DISEASE: NETWORK-BASED GENE EXPRESSION ANALYSIS. Alzheimer's and Dementia, 2019, 15, P57.	0.8	0

#	ARTICLE	IF	CITATIONS
91	ICâ€Pâ€060: GLOBAL CORTICAL [F18]FLORTALUCIPIR ASSOCIATION WITH THE TOP 20 ALZHEIMER'S DISEASE RISK GENES. Alzheimer's and Dementia, 2019, 15, P59.	0.8	0
92	ICâ€Pâ€063: A TOPOGRAPHIC IMAGING BIOMARKER OF TDP43 PATHOLOGY IN AMNESTIC DEMENTIA BASED ON AUTOPSYâ€DERIVED FDGâ€PET PATTERNS. Alzheimer's and Dementia, 2019, 15, P61.	0.8	3
93	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	21.4	192
94	Altered bile acid profile associates with cognitive impairment in Alzheimer's diseaseâ€”An emerging role for gut microbiome. Alzheimer's and Dementia, 2019, 15, 76-92.	0.8	396
95	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimer's and Dementia, 2019, 15, 232-244.	0.8	198
96	Codon bias among synonymous rare variants is associated with Alzheimerâ€™s disease imaging biomarker. , 2018, , .		6
97	Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis. JAMA Neurology, 2018, 75, 328.	9.0	101
98	F3â€02â€02: CIRCULATING METABOLITESâ€™ ASSOCIATION WITH ALZHEIMER'S DISEASEâ€”ASSOCIATED GENETIC VARIANTS. Alzheimer's and Dementia, 2018, 14, P997.	0.8	0
99	P4â€099: MULTIVARIATE CLUSTER PROFILING OF AMYLOID BETA, TAU, NEURODEGENERATION AND VASCULAR (ATNV) BIOMARKERS IN THE ADNI COHORT: IMPLICATIONS FOR COGNITION, â€™OMICS AND CLINICAL TRIALS. Alzheimer's and Dementia, 2018, 14, P1475.	0.8	0
100	P3â€120: DNA METHYLATION DYNAMICS IN ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOMARKERS AND NOVEL DRUG TARGETS USING ADNI EPIGENETIC DATA. Alzheimer's and Dementia, 2018, 14, P1113.	0.8	0
101	P2â€253: <i>EP300</i> IS ASSOCIATED WITH ALTERED BILE ACIDS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P772.	0.8	0
102	P2â€003: ACETYLCHOLINESTERASE INHIBITOR THERAPY IN MILD COGNITIVE IMPAIRMENT: YES OR NO?. Alzheimer's and Dementia, 2018, 14, P665.	0.8	0
103	P1â€143: MULTIVARIATE GENOMEâ€WIDE ASSOCIATION STUDY OF CSF BIOMARKERS FOR ALZHEIMER'S DISEASE IDENTIFIES VARIANTS IN HLA CLASS I REGION PROVIDING FURTHER EVIDENCE FOR THE ROLE OF IMMUNE FUNCTION. Alzheimer's and Dementia, 2018, 14, P330.	0.8	0
104	ICâ€Pâ€047: ASSOCIATIONS BETWEEN CORTICAL THICKNESS AND METAMEMORY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P46.	0.8	0
105	F3â€02â€01: ALTERED BILE ACID METABOLITES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE: RELATION TO NEUROIMAGING AND CSF BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P997.	0.8	0
106	P1â€153: DIACYLGLYCEROL PATHWAYâ€RELATED GENE <i>PNPLA2</i> IS ASSOCIATED WITH CSF BIOMARKERS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P335.	0.8	0
107	P3â€105: GENETIC VARIATION OF ANTIâ€AGING GENE <i>FGF23</i> IS ASSOCIATED WITH LARGER CORTICAL THICKNESS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1107.	0.8	0
108	O4â€01â€06: WHOLEâ€EXOME ANALYSIS OF LATEâ€ONSET ALZHEIMER'S DISEASE REVEALS NOVEL CANDIDATE GENES INVOLVED IN COGNITIVE FUNCTION. Alzheimer's and Dementia, 2018, 14, P1402.	0.8	0

#	ARTICLE	IF	CITATIONS
109	ICâ€Pâ€072: GENETIC VARIATION OF ANTIâ€AGING GENE FGF23 IS ASSOCIATED WITH LARGER CORTICAL THICKNESS IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P64.	0.8	0
110	P2â€103: GENOMEâ€WIDE ASSOCIATION OF TOP ALZHEIMER'S DISEASE ENDOPHENOTYPES IN ADNI DATASET. <i>Alzheimer's and Dementia</i> , 2018, 14, P707.	0.8	0
111	ICâ€Pâ€070: GENOMEâ€WIDE ASSOCIATION OF TOP ALZHEIMER'S DISEASE ENDOPHENOTYPES IN ADNI DATASET. <i>Alzheimer's and Dementia</i> , 2018, 14, P62.	0.8	0
112	Rare variants in the splicing regulatory elements of EXOC3L4 are associated with brain glucose metabolism in Alzheimerâ€™s disease. <i>BMC Medical Genomics</i> , 2018, 11, 76.	1.5	12
113	Quantitative trait loci identification for brain endophenotypes via new additive model with random networks. <i>Bioinformatics</i> , 2018, 34, i866-i874.	4.1	11
114	Exome Chip Analysis Identifies Low-Frequency and Rare Variants in <i>MRPL38</i> for White Matter Hyperintensities on Brain Magnetic Resonance Imaging. <i>Stroke</i> , 2018, 49, 1812-1819.	2.0	17
115	Longitudinal Genotypeâ€Phenotype Association Study through Temporal Structure Auto-Learning Predictive Model. <i>Journal of Computational Biology</i> , 2018, 25, 809-824.	1.6	6
116	A Longitudinal Imaging Genetics Study of Neuroanatomical Asymmetry in Alzheimerâ€™s Disease. <i>Biological Psychiatry</i> , 2018, 84, 522-530.	1.3	46
117	Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. <i>PLoS Medicine</i> , 2018, 15, e1002482.	8.4	336
118	Codon bias among synonymous rare variants is associated with Alzheimer's disease imaging biomarker. <i>Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing</i> , 2018, 23, 365-376.	0.7	6
119	Genetic variation affecting exon skipping contributes to brain structural atrophy in Alzheimer's disease. <i>AMIA Summits on Translational Science Proceedings</i> , 2018, 2017, 124-131.	0.4	6
120	Adult neurogenesis and neurodegenerative diseases: A systems biology perspective. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 93-112.	1.7	130
121	Novel genetic loci associated with hippocampal volume. <i>Nature Communications</i> , 2017, 8, 13624.	12.8	250
122	Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1245-1254.	2.6	54
123	Tissue-specific network-based genome wide study of amygdala imaging phenotypes to identify functional interaction modules. <i>Bioinformatics</i> , 2017, 33, 3250-3257.	4.1	23
124	Metabolic network failures in Alzheimer's disease: A biochemical roadÂmap. <i>Alzheimer's and Dementia</i> , 2017, 13, 965-984.	0.8	362
125	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 60, 92-103.	3.1	70
126	[P3â€087]: MICRORNA AND GENE NETWORKS UNDERLYING THE INVERSE ASSOCIATION OF CANCER AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P966.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Alzheimer's disease genetic risk variants beyond APOE ϵ 4 predict mortality. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 188-195.	2.4	8
128	[P4â€“420]: DEVELOPMENT OF A TAU BIOLOGICAL NETWORK FOR GENETIC ANALYSIS OF TAUOPATHIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1492.	0.8	0
129	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease. <i>BMC Medical Genomics</i> , 2017, 10, 29.	1.5	28
130	Knowledge-driven binning approach for rare variant association analysis: application to neuroimaging biomarkers in Alzheimer's disease. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 61.	3.0	16
131	Comparing Variability, Severity, and Persistence of Depressive Symptoms as Predictors of Future Stroke Risk. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 120-128.	1.2	17
132	Two-dimensional enrichment analysis for mining high-level imaging genetic associations. <i>Brain Informatics</i> , 2017, 4, 27-37.	3.0	13
133	[ICâ€“056]: <i>ADORA2A</i> POLYMORPHISM IS ASSOCIATED WITH CEREBRAL BLOOD FLOW IN MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P46.	0.8	0
134	[P3â€“088]: <i>KLK8</i> AS A MODULATOR OF ALZHEIMER'S DISEASE PATHOLOGY: NEUROIMAGING GENETICS. <i>Alzheimer's and Dementia</i> , 2017, 13, P966.	0.8	2
135	[P1â€“142]: DNA METHYLATION DYNAMICS IN ALZHEIMER'S DISEASE DIAGNOSIS AND PROGRESSION. <i>Alzheimer's and Dementia</i> , 2017, 13, P297.	0.8	3
136	[P1â€“151]: <i>VEGFA</i> IS ASSOCIATED WITH CEREBRAL BLOOD FLOW AND WHITE MATTER HYPERINTENSITY IN MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P300.	0.8	0
137	[ICâ€“063]: <i>KLK8</i> AS A MODULATOR OF ALZHEIMER'S DISEASE PATHOLOGY: NEUROIMAGING GENETICS. <i>Alzheimer's and Dementia</i> , 2017, 13, P51.	0.8	1
138	[P2â€“111]: <i>ADORA2A</i> POLYMORPHISM IS ASSOCIATED WITH CEREBRAL BLOOD FLOW IN MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P649.	0.8	0
139	[P2â€“220]: GENETIC FINDINGS USING ADNI MULTIMODAL QUANTITATIVE PHENOTYPES: A 2016 UPDATE. <i>Alzheimer's and Dementia</i> , 2017, 13, P694.	0.8	0
140	[F1â€“02â€“04]: INTEGRATING MULTI-MODALITY IMAGING AND MULTI-LAYER OMICS TO ADVANCE THE SYSTEMS BIOLOGY OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P175.	0.8	0
141	[O1â€“11â€“02]: GENOME-WIDE ASSOCIATION ANALYSIS OF TAU ACCUMULATION IDENTIFIES ENRICHMENT OF NEUROGENESIS-RELATED PATHWAYS. <i>Alzheimer's and Dementia</i> , 2017, 13, P217.	0.8	0
142	[F2â€“01â€“03]: GUT DERIVED BILE ACID METABOLITES CORRELATE WITH STRUCTURAL AND FUNCTIONAL NEUROIMAGING MEASURES IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P543.	0.8	0
143	Longitudinal Genotype-Phenotype Association Study via Temporal Structure Auto-learning Predictive Model. <i>Lecture Notes in Computer Science</i> , 2017, 10229, 287-302.	1.3	8
144	Transcriptome-Guided Imaging Genetic Analysis via a Novel Sparse CCA Algorithm. <i>Lecture Notes in Computer Science</i> , 2017, 10551, 220-229.	1.3	5

#	ARTICLE	IF	CITATIONS
145	Genome-wide association study of language performance in Alzheimer's disease. <i>Brain and Language</i> , 2017, 172, 22-29.	1.6	20
146	Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 991-1003.	2.6	12
147	Reply. <i>Annals of Neurology</i> , 2016, 79, 335-335.	5.3	0
148	The effect of the top 20 Alzheimer disease risk genes on gray matter density and FDG PET brain metabolism. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 53-66.	2.4	35
149	O112: Identification of Discriminative Brain Imaging and Genomic Associations: an Alzheimer's Disease Study. <i>Alzheimer's and Dementia</i> , 2016, 12, P205.	0.8	0
150	P1007: Association of FDG PET Brain Metabolism with Alzheimer's Disease Risk Genes. <i>Alzheimer's and Dementia</i> , 2016, 12, P399.	0.8	0
151	IC0201: The Effects of The Top 20 Alzheimer's Disease Risk Genes on Brain Atrophy. <i>Alzheimer's and Dementia</i> , 2016, 12, P4.	0.8	0
152	ICP059: Examining The Effect of The Top 20 Ad Risk Variants on Brain Amyloidosis, Structural Atrophy and Metabolism. <i>Alzheimer's and Dementia</i> , 2016, 12, P47.	0.8	0
153	IC-P061: Alzheimer's Disease Risk Genes Can Predict Brain Amyloidosis. , 2016, 12, P49-P50.		0
154	ICP070: Predicting Cognitive Decline and Brain Amyloidosis Using Cognitive and Peripheral Blood Gene Expression Measures. <i>Alzheimer's and Dementia</i> , 2016, 12, P55.	0.8	0
155	ICP072: Gene Expression Of ABCA7 Dysregulated in Peripheral Blood is Associated With Decreased Metabolic Activity in Hippocampus. <i>Alzheimer's and Dementia</i> , 2016, 12, P56.	0.8	0
156	ICP074: Genome-Wide Meta-Analysis of Transcriptome Profiling Identifies Novel Dysregulated Genes Implicated in Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P58.	0.8	0
157	ICP075: The Growth and Impact of ADNI Genetics Publications as Measured by Science Mapping. <i>Alzheimer's and Dementia</i> , 2016, 12, P60.	0.8	0
158	P2074: A Meta-Analysis Identifies <i>ADORA2A</i> Associated with Hippocampal Volume in Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P636.	0.8	1
159	P2098: Whole Brain Surface-Based Analysis Identified Brain Atrophy Associated with SNPs in <i>FRMD6</i> Linked to Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P648.	0.8	2
160	IC-P-109: Plasma TAU Levels in Mild Cognitive Impairment and Alzheimer's Disease. , 2016, 12, P82-P83.		0
161	P2233: Alzheimer's Disease Risk Genes Can Predict Brain Amyloidosis. <i>Alzheimer's and Dementia</i> , 2016, 12, P712.	0.8	0
162	P2249: Predicting Cognitive Decline and Brain Amyloidosis using Cognitive and Peripheral Blood Gene Expression Measures. <i>Alzheimer's and Dementia</i> , 2016, 12, P720.	0.8	0

#	ARTICLE	IF	CITATIONS
163	P2â€253: The Effects of the Top 20 Alzheimer's Disease Risk Genes on Brain Atrophy. Alzheimer's and Dementia, 2016, 12, P722.	0.8	0
164	P2â€258: The Growth and Impact of ADNI Genetics Publications as Measured by Science Mapping. Alzheimer's and Dementia, 2016, 12, P725.	0.8	0
165	P3â€087: Gene Expression of <i>ABCA7</i> Dysregulated in Peripheral Blood is Associated With Decreased Metabolic Activity in Hippocampus. Alzheimer's and Dementia, 2016, 12, P851.	0.8	0
166	P3-089: Influence of Parkinsonâ€™s Disease Candidate Genes On Lewy Body Pathology in Autopsy-Confirmed Alzheimer's Disease Cases. , 2016, 12, P854-P854.		0
167	F1-02-02: Genetic Influence on Levels of Targeted Metabolites Associated with Alzheimerâ€™s Disease. , 2016, 12, P164-P165.		0
168	O2-06-02: Genome-Wide Meta-Analysis of Transcriptome Profiling Identifies Novel Dysregulated Genes Implicated in Alzheimer's Disease. , 2016, 12, P238-P239.		0
169	O2â€10â€01: Genomeâ€Wide Association Analysis of Hippocampal Volume Identifies Enrichment of Neurogenesisâ€Related Pathways. Alzheimer's and Dementia, 2016, 12, P250.	0.8	0
170	O4â€10â€04: Plasma TAU Levels in Mild Cognitive Impairment and Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P358.	0.8	0
171	O5â€01â€04: EXAMINING THE EFFECT OF THE TOP 20 ALZHEIMER'S DISEASE RISK VARIANTS ON BRAIN AMYLOIDOSIS, STRUCTURAL ATROPHY AND METABOLISM. Alzheimer's and Dementia, 2016, 12, P376.	0.8	1
172	P1-117: Blood Gene Expression Changes Implicated in Alzheimerâ€™s Disease. , 2016, 12, P448-P448.		0
173	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	14.8	213
174	Alpha-synuclein (SNCA) polymorphisms exert protective effects on memory after mild traumatic brain injury. Neuroscience Letters, 2016, 630, 241-246.	2.1	3
175	ICâ€Pâ€066: Association of FDGâ€PET Brain Metabolism with Alzheimerâ€™s Disease Risk Genes. Alzheimer's and Dementia, 2016, 12, P52.	0.8	1
176	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimerâ€™s disease. BMC Medical Genomics, 2016, 9, 30.	1.5	20
177	Genomics and CSF analyses implicate thyroid hormone in hippocampal sclerosis of aging. Acta Neuropathologica, 2016, 132, 841-858.	7.7	28
178	Hippocampal Sclerosis of Aging, a Common Alzheimerâ€™s Disease â€Mimicâ€™: Risk Genotypes are Associated with Brain Atrophy Outside the Temporal Lobe. Journal of Alzheimer's Disease, 2016, 52, 373-383.	2.6	23
179	P2-132: Association of cerebral microhemorrhages with amyloid deposition and hyperlipidemia. , 2015, 11, P534-P535.		0
180	IC-P-042: Influence of rare reelin variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer's disease. , 2015, 11, P36-P36.		1

#	ARTICLE	IF	CITATIONS
181	P1-201: Genetic findings using ADNI multimodal quantitative phenotypes: A 2014 update. , 2015, 11, P426-P426.		1
182	P3-014: Influence of rare RELN variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer's disease. , 2015, 11, P624-P625.		0
183	P4-191: Gwas identifies gli3 as a novel gene for language deficits and cortical changes in older adults at-risk for Alzheimer's disease. , 2015, 11, P853-P853.		0
184	P1-193: Anticholinergic medication use in older adults is associated with memory and hippocampal volume. , 2015, 11, P422-P422.		0
185	IC-P-035: Effect of hypertension and antihypertensive medication on executive function, brain atrophy, and white matter hyperintensities. , 2015, 11, P32-P33.		0
186	P4-008: Mapre2 as a novel Alzheimer's disease target gene from gwas of CSF amyloid beta 1-42, tau and hyperphosphorylated tau in the ADNI cohort. , 2015, 11, P767-P768.		3
187	IC-P-034: Anticholinergic medication use in older adults is associated with memory and hippocampal volume. , 2015, 11, P32-P32.		0
188	P4-197: Gene expression profiling identifies altered networks in late-onset Alzheimer's disease: Immune response and mitochondrial process. , 2015, 11, P855-P856.		0
189	O4-05-01: Gwas of longitudinal amyloid PET identifies IL1RAP as a new potential Alzheimer's disease target. , 2015, 11, P277-P278.		0
190	Reply. Annals of Neurology, 2015, 78, 662-663.	5.3	2
191	Reply. Annals of Neurology, 2015, 78, 499-500.	5.3	2
192	Reply. Annals of Neurology, 2015, 78, 836-837.	5.3	0
193	Comprehensive Gene- and Pathway-Based Analysis of Depressive Symptoms in Older Adults. Journal of Alzheimer's Disease, 2015, 45, 1197-1206.	2.6	33
194	IC-P-037: Association of cerebral microhemorrhages with amyloid deposition and hyperlipidemia. , 2015, 11, P33-P34.		0
195	O1-04-04: Effect of hypertension and antihypertensive medication on executive function, brain atrophy, and white matter hyperintensities. , 2015, 11, P133-P134.		0
196	P1-002: Transcriptome-guided neurogenesis gene pathway variation is associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. , 2015, 11, P336-P337.		0
197	P1-009: The nav2 (neuron navigator 2) gene as a common genetic influence across correlated episodic memory performances. , 2015, 11, P339-P340.		0
198	O3-13-04: Genome-wide rare variant analysis identifies candidate genes significantly associated with composite scores for memory. , 2015, 11, P251-P252.		1

#	ARTICLE	IF	CITATIONS
199	P4-195: Pathway-based gene analysis identifies vegfa as a gene associated with cerebral blood flow in Alzheimer's disease. , 2015, 11, P855-P855.		0
200	Cortical surface biomarkers for predicting cognitive outcomes using group l2,1 norm. Neurobiology of Aging, 2015, 36, S185-S193.	3.1	43
201	Protective variant for hippocampal atrophy identified by whole exome sequencing. Annals of Neurology, 2015, 77, 547-552.	5.3	48
202	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	27.8	772
203	Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimer's and Dementia, 2015, 11, 792-814.	0.8	241
204	Hippocampal transcriptome-guided genetic analysis of correlated episodic memory phenotypes in Alzheimer's disease. Frontiers in Genetics, 2015, 6, 117.	2.3	23
205	<i>APOE</i> effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimer's and Dementia, 2015, 11, 1417-1429.	0.8	157
206	Two-Dimensional Enrichment Analysis for Mining High-Level Imaging Genetic Associations. Lecture Notes in Computer Science, 2015, 9250, 115-124.	1.3	1
207	GWAS of longitudinal amyloid accumulation on ¹⁸ F-florbetapir PET in Alzheimer's disease implicates microglial activation gene <i>IL1RAP</i> . Brain, 2015, 138, 3076-3088.	7.6	117
208	Comparison of multi-sample variant calling methods for whole genome sequencing. , 2014, 2014, 59-62.		11
209	Gene-based GWAS and biological pathway analysis of the resilience of executive functioning. Brain Imaging and Behavior, 2014, 8, 110-118.	2.1	33
210	Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging and Behavior, 2014, 8, 183-207.	2.1	161
211	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging and Behavior, 2014, 8, 153-182.	2.1	696
212	Late-Onset Alzheimer's Disease, Heating up and Foxed by Several Proteins: Pathomolecular Effects of the Aging Process. Journal of Alzheimer's Disease, 2014, 40, 1-17.	2.6	30
213	P3-024: NEXT-GENERATION SEQUENCING OF THE BCHE LOCUS IDENTIFIES A FUNCTIONAL SNP ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS AND AGE OF ONSET. , 2014, 10, P636-P636.		0
214	IC-01-03: Hippocampal transcriptome-guided gene-gene interaction of memory phenotype in MCI and Alzheimer's disease. , 2013, 9, P4-P4.		0
215	Influence of <i>TSPO</i> Genotype on ¹¹ C-PBR28 Standardized Uptake Values. Journal of Nuclear Medicine, 2013, 54, 1320-1322.	5.0	56
216	The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Frontiers in Aging Neuroscience, 2013, 5, 11.	3.4	126

#	ARTICLE	IF	CITATIONS
217	PARP1 Gene Variation and Microglial Activity on [11C]PBR28 PET in Older Adults at Risk for Alzheimer's Disease. Lecture Notes in Computer Science, 2013, 8159, 150-158.	1.3	8
218	Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel. PLoS ONE, 2013, 8, e70269.	2.5	50
219	Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics, 2012, 44, 552-561.	21.4	594
220	Genetic architecture of resilience of executive functioning. Brain Imaging and Behavior, 2012, 6, 621-633.	2.1	22
221	Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging and Behavior, 2012, 6, 634-648.	2.1	58
222	Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease. Brain Imaging and Behavior, 2012, 6, 551-567.	2.1	66
223	Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging and Behavior, 2012, 6, 568-583.	2.1	47
224	Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging and Behavior, 2012, 6, 1-15.	2.1	47
225	The Interleukin 3 Gene (IL3) Contributes to Human Brain Volume Variation by Regulating Proliferation and Survival of Neural Progenitors. PLoS ONE, 2012, 7, e50375.	2.5	33
226	Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimer's and Dementia, 2010, 6, 265-273.	0.8	378
227	O3-03-01: Genome-wide association study of CSF biomarkers amyloid beta 1-42, tau and tau phosphorylated at threonine 181 in the ADNI cohort. , 2010, 6, S129-S129.		1
228	O3-06-01: Association analysis of candidate SNPs on hippocampal volume and shape in mild cognitive impairment and older adults with cognitive complaints. , 2010, 6, S137-S138.		1
229	Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. NeuroImage, 2010, 53, 1051-1063.	4.2	340
230	Superfluidity of Mesoscopic Bose Gases under Varying Confinements. Physical Review Letters, 2005, 95, 193601.	7.8	15
231	Nematic Phase of the Two-Dimensional Electron Gas in a Magnetic Field. Physical Review Letters, 2000, 84, 1982-1985.	7.8	116
232	Critical behavior of the planar magnet model in three dimensions. Physical Review B, 1999, 59, 11575-11578.	3.2	9